You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

Displaying 201431 - 201440 of 202203 results
  1. Rapid, Near-Tranfusion Test for Bacteria in Platelets Units

    SBC: IMMUNETICS, INC.            Topic: NHLBI

    DESCRIPTION (provided by applicant): Bacterial contamination of platelets is considered the greatest infectious risk of blood product transfusion today at about 1 in 2000 platelet units, which is several orders of magnitude greater than that of HIV. Bacterial contamination at high levels can lead to severe morbidity or mortality in transfusion recipients. The American Association of Blood Banks is ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  2. Novel Micro-Implant to Measure Intracardiac Pressure in Congenital Heart Patients

    SBC: Integrated Sensing Systems Incorporated            Topic: NHLBI

    DESCRIPTION (provided by applicant): PROJECT SUMMARY Congenital heart disease patients with functional single ventricle (FSV) anatomy ultimately require a Fontan operation for long term survival. The goal of the Fontan operation is to re-route systemic venous blood to the pulmonary circulation without passing through an intervening ventricular chamber. As a result, blood flow to the lungs is almos ...

    SBIR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  3. Development of a Prophylactic Onchocerciasis Vaccine

    SBC: PAI Life Sciences, Inc.            Topic: NIAID

    Humanriver blindnessis caused by a filarial parasite and is a serious neglected tropical disease contributing to blindnessskin diseaseand chronic disability in the developing worldEstimates from the Global Burden of Disease Studyindicate thatmillion cases of onchocerciasisleading tomillion cases of vision impairmentoccur worldwide every yearThe goal of this project is to develop a safe and effecti ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  4. Development of a novel SP-B peptide lung surfactant

    SBC: Molecular Express Inc            Topic: NHLBI

    DESCRIPTION (provided by applicant): This competitive renewal SBIR proposal extends our current Phase II translational research on novel synthetic lipid/peptide lung surfactants containing the highly active Super Mini-B (S-MB) peptide incorporating crucialfunctional regions of human surfactant protein (SP)-B, the most active apoprotein in biologic surfactant. Our initial Phase II grant focused on ...

    SBIR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health
  5. Attack Major Source of Abused Opioids: Molecularly Deactivate Unused Rx Opioids

    SBC: ELYSIUM THERAPEUTICS, INC.            Topic: NIDA

    Project SummaryAbstractAddiction is a diseaseAccording to the National Institute on Drug Abuseaddiction can be hereditaryand canbetriggeredbyenvironmentalconditionsandbehaviorOnekeyenvironmentalfactorinvolvesthereadyaccess to unused prescription opioids by potential abusersespecially teensElysium has discovered a novel molecular deactivationXpiRxorexpiring pilltechnology that is designedto effecti ...

    SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  6. Diagnostic array for aseptic encephalitis

    SBC: AKONNI BIOSYSTEMS INC            Topic: NIAID

    DESCRIPTION provided by applicant Encephalitis and meningitis are potentially fatal diseases defined by acute inflammation of the brain or protective membranes covering the brain and spinal cord These diseases can be caused by viruses bacteria fungi parasites or amoeba and disproportionately affect children the elderly or the immunocompromised Viruses are the most common cause of enceph ...

    SBIR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  7. Bone targeted delivery of an antimicrobial drug for osteomyelitis therapy

    SBC: BIOVINC, LLC            Topic: NIAID

    ABSTRACTIn general, the incidence of osteomyelitis is around 1-2% in patients undergoing total knee and hip replacement surgeries. When patients have to undergo revision therapy to replace infected implants, mortality is 18%. Due to the aging of the population in the US, and the increase in the number of total joint arthroplasties in this population, the annual cost of infected revision surgeries ...

    SBIR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health
  8. Infection Site Targeted Antitoxin Antibody (ISTAb) against Bacillus anthracis

    SBC: Integrated Biotherapeutics, Inc.            Topic: NIAID

    Project Summary Bacillus anthracis (Ba) is a Gram-positive spore forming bacterium that is listed as an agent of highest concern (Category A) by NIAID and CDC. Ba is easy to grow, and its spores can be formulated into highly stable powder form and disseminated as aerosol or used to contaminate food or water. In 2001, letters laced with powdered anthrax spores were mailed to several US politicians. ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  9. Marketing Strategic Plan and Distribution Logistics for Sanaria PfSPZ Vaccine against Malaria.

    SBC: SANARIA INC.            Topic: NIAID

    ABSTRACT The development of Sanaria s Plasmodium falciparumPfsporozoiteSPZbased vaccines is receiving overwhelming global support after the publication inin Science of clinical data showingprotection against controlled human malaria infectionCHMIfollowing intravenous administration ofdoses of SanariaPfSPZ Vaccinecomposed of purifiedasepticradiation attenuatedcryopreserved PfSPZ meeting all regulat ...

    SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  10. Highly Efficient and Compact Microclimate Cooling System for Encapsulated Personal Protection Ensemble

    SBC: RINI TECHNOLOGIES INC            Topic: A02196

    In this Phase II effort, RTI will develop an Ultra compact and lightweight solider cooling system for the Future Force Warrior program. The development effort proposed here targets newer technology enabled by recent advances in miniaturization technology in order to offer the design of a complete microclimate system, the performance of which cannot be matched simply by using smaller versions of cu ...

    SBIR Phase II 2004 Department of DefenseArmy
US Flag An Official Website of the United States Government